NASDAQ: XFORX4 Pharmaceuticals Inc Stock
$2.71-0.21 (-7.19%)
Updated May 20, 2025
XFOR Price
$2.71
Fair Value Price
-$0.11
Market Cap
$15.69M
52 Week Low
$2.67
52 Week High
$33.90
P/E
1.27x
P/B
0.68x
P/S
1.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$31.36M
Earnings
$14.60M
Gross Margin
82.4%
Operating Margin
76.58%
Profit Margin
46.5%
Debt to Equity
4.67
Operating Cash Flow
-$110M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XFOR Overview
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XFOR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XFOR
Ranked#370 of 454
Ranked#370 of 454
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.20 | A | |
| $8.30 | A | |
| $65.30 | A |
Be the first to know about important XFOR news, forecast changes, insider trades & much more!
XFOR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XFOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XFOR ($2.71) is overvalued by 2,647.24% relative to our estimate of its Fair Value price of -$0.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XFOR ($2.71) is not significantly undervalued (2,647.24%) relative to our estimate of its Fair Value price of -$0.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XFOR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more XFOR due diligence checks available for Premium users.
Valuation
XFOR fair value
Fair Value of XFOR stock based on Discounted Cash Flow (DCF)
Price
$2.71
Fair Value
-$0.11
Undervalued by
2,647.24%
XFOR ($2.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XFOR ($2.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XFOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.27x
Industry
-156.07x
Market
25.56x
XFOR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
XFOR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
XFOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.68x
Industry
4.37x
XFOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XFOR's financial health
Profit margin
Revenue
$28.8M
Net Income
$282.0k
Profit Margin
1%
XFOR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$130.0M
Liabilities
$107.1M
Debt to equity
4.67
XFOR's short-term assets ($95.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XFOR's short-term assets ($95.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XFOR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XFOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.4M
Investing
-$3.1M
Financing
$0.0
XFOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XFOR vs Biotech Stocks
X4 Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.